In mouse models of DIPG, simultaneously attacking two metabolic pathways led to significant improvements in survival.
Anti-androgen therapy showed positive results in cell lines and animal models.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against these aggressive brain tumors.
In mouse models with a deadly form of pediatric brain cancer, an immune stimulatory gene therapy increased median survival.
When researchers study rare diseases, breakthroughs can be made that help patients. Revisit studies that are putting genetic puzzle pieces together to tackle these conditions.